ExpreS2ion Biotech Holding AB
EXPRS2
Company Profile
Business description
ExpreS2ion Biotech Holding AB has developed a technology platform, ExpreS2, for fast and efficient non-clinical development and production of complex proteins for new vaccines and diagnostics. ExpreS2 is regulatorily validated for clinical supply. The platform includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. The company has produced more than 500 proteins and virus-like particles (VLPs) in collaboration with research institutions and companies.
Contact
c/o Mindpark
Ronnowsgatan 8c
HelsingborgS-252 25
SWET: +45 22221019
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
19
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,510.10 | 10.10 | -0.12% |
| CAC 40 | 7,836.79 | 37.04 | -0.47% |
| DAX 40 | 23,527.01 | 111.55 | -0.47% |
| Dow JONES (US) | 42,051.06 | 89.37 | -0.21% |
| FTSE 100 | 8,585.01 | 17.91 | -0.21% |
| HKSE | 23,679.17 | 38.52 | 0.16% |
| NASDAQ | 19,146.81 | 136.72 | 0.72% |
| Nikkei 225 | 37,704.10 | 424.03 | -1.11% |
| NZX 50 Index | 12,812.08 | 32.82 | 0.26% |
| S&P 500 | 5,892.58 | 6.03 | 0.10% |
| S&P/ASX 200 | 8,277.20 | 2.40 | -0.03% |
| SSE Composite Index | 3,393.47 | 10.47 | -0.31% |